Miami, FL – July 28, 2020 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, reports on PetVivo Holdings, Inc. (OTCQB: PETV).
PetVivo Checks-in on its Pet Patients Years Later and Finds Beautiful Results.
PetVivo Holdings INC. OTC QB (PETV) is going back to the happy owners of dogs and horses who were lucky enough to try its lead product KUSH, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs and horses scheduled for commercial launch later this year.
In an effort to assemble a summary of case studies for the benefit of regular and orthopedic veterinarians throughout the U.S., PetVivo is going back to the owners of past patients to observe and follow-up on their health.
In one recent interview conducted via zoom with John Lai, PetVivo’s Chief Executive Officer, and Chris Cattone, the owner of a dog named “Hope”, John and Chris discussed Hope’s injection experience and the results thereafter. Chris remembered the veterinarian giving two choices for Hope, either heavy pain killers or significant surgery. Both of these options did not feel right as Hope was just two years young.
Hope’s owners were nervous and unsure of what to do until learning about something unique upon meeting John Lai. John had tremendous experience in helping older dogs and horses who developed osteoarthritis but Hope’s case was a genetics issue affecting her at 1-year and nine months of age.
John was able to set Chris and his dog Hope up with Dr. Michael Fusco, a Miami veterinarian, familiar with intraarticular injections, such as KUSH. Dr. Fusco injected both hind legs as the rear right was compensating for the lameness in her left back leg. Dr. Fusco took X-rays and decided KUSH was a viable treatment. After less than two weeks, Hope was showing improved strength with a definite increase in mobility. Within a month, the right keg and left were the same size, and she had no pain.
Seven years have gone by since that first injection of KUSH and with only a single injection in both joints, Hope is still running strong.
John Lai and his PetVivo team are currently launching into the commercial market with KUSH and recently in late February, 2020 presented at the Western Veterinary Conference (“WVC”) in Las Vegas Nevada. Following the WVC John stated. “I believe our product can enhance the quality of life for so many dogs and horses; I believe it is our responsibility to treat as many animals as possible.”
You can see the results and hear from John and Chris speaking about Chris’ beautiful dog Hope right here.
If you suspect your dog may be exhibiting signs of osteoarthritis, it is essential to have your dog evaluated by a veterinarian, who will perform a full physical examination, including palpating your dog’s joints and assessing their range of motion. Your veterinarian may also recommend X-rays of the affected joints, which will help rule out other conditions that can cause similar symptoms. X-rays can also help your veterinarian evaluate the degree of damage to the joint.
PetVivo is currently running a unique program for pet patients, their owners, and their current veterinarians. This program is a win for all three. Therefore, if you have an interest to learn more about KUSH or possibly give it a try, please have your veterinarian contact John Lai for more information and to learn about any special offers related to KUSH.
Learn more and participate in this new, innovative and incredibly beneficial treatment for osteoarthritis.
PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes, and biomaterials.
(All Press Releases Will Be Available for Viewing on the Web at www.petvivo.com )
John Lai, CEO
PetVivo Holdings, Inc.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements
EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.